Anita Giobbie-Hurder is an expert in Oncology at Dana-Farber Cancer Institute (United States). As of September 2026, ScienceLeadR ranks Anita Giobbie-Hurder in the top 1% of experts worldwide for Skin Neoplasms. Anita Giobbie-Hurder has authored 329 publications, the most recent in 2026, and is an investigator in 28 clinical trials. SLR score: 1,143 (community average: 125). How the SLR is computed.

LeadR Profile

Anita Giobbie-Hurder Dana-Farber Cancer Institute United States
1 143 ScienceLeadR Reputation 1143
Network Map

Oncology

Subspecialties: Dermatology - Immunology - Hematology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 2006 - 2026

Source: PubMed

Dana-Farber Cancer Institute

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 329

Citations

Citations: 24 547 1st author: 3 Last author: 5 Unique author: 0


Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Progression patterns and clinical outcomes in patients with cutaneous squamous-cell carcinoma following anti-PD-1 therapy failure.
PMID 41819748 — cells, cetuximab, carcinoma, squamous cell, neoplasms, drug therapy, immunotherapy, therapeutics, chemotherapy, cutaneous squamous cell carcinoma
ESMO Open20260
Graph neural network modeling of spatial tumor-immune interactions identifies prognostic cellular niches in non‑small cell lung cancer.
PMID 41794974 — cells, lung, neoplasms, carcinoma, non-small-cell lung, lung neoplasms, small cell lung carcinoma
NPJ Precis Oncol20260
Barriers to the Adoption of Healthy Lifestyle Behaviors in Patients With Cancer: Results of a National Survey.
PMID 41701954 — life style, healthy lifestyle, neoplasms, diagnosis, therapeutics
JCO Oncol Pract20260
Phase II trial of cabozantinib in combination with nivolumab for advanced extrapancreatic neuroendocrine tumors (epNET).
PMID 41263691 — cells, safety, neoplasms, nivolumab, neuroendocrine tumors
Clin Cancer Res20250
Pan-cancer spatial characterization of key immune biomarkers in the tumor microenvironment.
PMID 41092903 — neoplasms, biomarkers, tumor microenvironment
Cell Rep Med20251

Clinical Studies 28

Sources: ClinicalTrials, EU CTIS

Synthesis

By phase:

Phase 2 10
N/A 7
Phase 1 6
Phase 1/Phase 2 3
Phase 3 2

By status:

Completed 21
Active not recruiting 6
Terminated 1

By type:

Interventional 28

By Monocentric/Multicentric:

monocentric 10
multicentric2to4 10
multicentric5to9 4
multicentricup10 4

Main Topics

Cohort/Consortium Investigators 1

LeadR Networks

Main global connection map